ImreNothMD
Pulmonology • Charlottesville, VACritical Care Medicine, Interstitial Lung Diseases, Pleural Disease
Professor of Medicine
Dr. Noth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1221 Hospital Dr
Fl 2
Charlottesville, VA 22908Phone+1 434-924-5219Fax+1 434-244-7509
Education & Training
University of ChicagoFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1999
University of California Davis HealthResidency, Internal Medicine, 1992 - 1995
University of Arizona College of MedicineClass of 1992
Certifications & Licensure
AZ State Medical License 1995 - Present
CA State Medical License 1993 - Present
VA State Medical License 2018 - 2026
IL State Medical License 1996 - 2020- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations Start of enrollment: 2005 Jan 01
- A Study of the Natural Progression of Interstitial Lung Disease (ILD) Start of enrollment: 2005 Sep 01
- Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis Start of enrollment: 2007 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.Lindsay Somerville, Larry Borish, Imre Noth, Dana Albon
Therapeutic Advances in Respiratory Disease. 2024-11-15 - Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.R Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Eric S White
ERJ Open Research. 2024-11-01 - 1 citationsPreacinar Arterial Dilation Mediates Outcomes of Quantitative Interstitial Abnormalities in the COPDGene Study.Eileen M Harder, Pietro Nardelli, Carrie L Pistenmaa, Samuel Y Ash, Aparna Balasubramanian
American Journal of Respiratory and Critical Care Medicine. 2024-11-01
Other
- Management of the patient with severe COPD and cardiovascular diseaseNoth I, Schmidt GA
http://www.uptodate.com/contents/management-of-the-patient-with-severe-copd-and-cardiovascular-disea
UpToDate, Wolters Kluwer Health - 2013-02-12
Press Mentions
iTHRIV Backs Promising Researchers to Improve Patient CareJune 10th, 2024- Antibiotics Won't Help Fight Lung-Scarring Disease IDF: StudyJune 4th, 2021
Ofev Doubles the Chance of Improving or Stabilizing IPFMay 26th, 2017- Join now to see all
Grant Support
- Genome-Wide Association And EXON Sequencing Study In IPFNational Heart, Lung, And Blood Institute2009–2010
- Combination Therapy In IPFNational Heart, Lung, And Blood Institute2005–2009
- FP And Salmeterol In Preventing COPD ExacerbationsNational Center For Research Resources2006–2007
Other Languages
- Hebrew
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
